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 1.  Introduction 
 Circulating tumor cells (CTCs) have recently gained atten-
tion as a useful prognostic tool in cancer patients. They have 
been identifi ed as useful predictors of metastasis and multiple 
studies have demonstrated their potential in determining 
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 Circulating tumor cells (CTCs) are believed to play an important role in metastasis, 
a process responsible for the majority of cancer-related deaths. But their rarity in the 
bloodstream makes microfl uidic isolation complex and time-consuming. Additionally 
the low processing speeds can be a hindrance to obtaining higher yields of CTCs, 
limiting their potential use as biomarkers for early diagnosis. Here, a high throughput 
microfl uidic technology, the OncoBean Chip, is reported. It employs radial fl ow that 
introduces a varying shear profi le across the device, enabling effi cient cell capture by 
affi nity at high fl ow rates. The recovery from whole blood is validated with cancer 
cell lines H1650 and MCF7, achieving a mean effi ciency >80% at a throughput of 
10 mL h −1 in contrast to a fl ow rate of 1 mL h −1 standardly reported with other 
microfl uidic devices. Cells are recovered with a viability rate of 93% at these high 
speeds, increasing the ability to use captured CTCs for downstream analysis. Broad 
clinical application is demonstrated using comparable fl ow rates from blood 
specimens obtained from breast, pancreatic, and lung cancer patients. Comparable 
CTC numbers are recovered in all the samples at the two fl ow rates, demonstrating 
the ability of the technology to perform at high throughputs. 
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prognosis in metastatic breast, colorectal and prostate can-
cers. [ 1 ] Cristofanilli et al. showed that CTCs can predict sur-
vival in metastatic breast cancer patients. [ 2 ] In ovarian cancer, 
Fan et al. found that stage III/IV (advanced stage) cancer 
patients exhibited a higher mean CTC count than stage I/
II patients, suggesting that elevated numbers of CTCs were 
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present in more advanced stages of disease. [ 3 ] CTCs are thus 
useful candidates for clinical monitoring of cancer patients. 
However, their rarity (1–2 CTCs in 1 mL of blood containing 
∼10 9 blood cells) prevents important downstream analysis that 
could provide useful insights into tumor biology and metas-
tasis. [ 4–6 ] More effi cient processing of higher volumes of blood 
in order to obtain a signifi cant number of these cells thus 
becomes critical and has the potential to establish the role of 
CTCs as potential biomarkers for early detection of cancer. 
 CellSearch is currently the only FDA-approved platform 
for CTC detection available for clinical use. [ 1 ] It has success-
fully demonstrated clinical utility by monitoring CTCs in 
blood from patients with breast, colon and prostate cancer 
wherein it was shown that CTCs correlate with poor prog-
nosis. [ 1,7 ] CTCs have also been used as investigative bio-
markers in clinical trials; two recent clinical trials in lung 
cancer [ 8,9 ] analyzed CTC numbers to predict survival among 
patients undergoing treatment. Molecular analysis of the 
CTCs was performed by investigating mutations for primary 
tumor matching [ 8 ] or FISH analysis of the CTCs indicating 
the potential use of CTCs in determining mutation status of 
patients undergoing therapy. [ 9 ] CTCs were also investigated 
in a pancreatic cancer study to evaluate two different tech-
nologies for CTC isolation and the possible use of CTCs as 
a novel biomarker for tumors that are diffi cult to biopsy. [ 10 ] 
Following the initial success of using CTC technologies in 
predicting patient survival, [ 11 ] many microfl uidic CTC iso-
lation technologies [ 4,5,7,12–17 ] have been developed to date 
employing immuno-affi nity or physical separation techniques, 
as they offer a more compact technology with effi cient use of 
resources. While sized-based and other physical separation 
techniques have been improved to obtain higher through-
puts over the years, they suffer from limitations related to the 
heterogeneity of the tumor cells, contamination with blood 
cells and result in lower yields and specifi city. [ 11 ] For example, 
CTCs within a patient may have a wide range of sizes 
(>4 to 30 µm) and many of them may overlap in size with that 
of the blood cells. [ 5 ] Affi nity-based isolation thus provides a 
more specifi c method for CTC enrichment and isolation. 
 Affi nity-based microfl uidics operate at low fl ow rates (1–3 
mL hr −1 ) due to shear constraints at high fl ow rates that may 
rupture antibody-antigen bonds. The CTC-chip, [ 6,18 ] which 
captures epithelial cancer cells circulating in blood at an 
operating fl ow rate of 1 mL hr −1 by using anti-Epithelial Cell 
Adhesion Molecule (anti-EpCAM) coated on microposts, 
was the fi rst successful immuno-affi nity based microfl uidic 
platform. Subsequently, a second generation platform was 
developed, known as the Herringbone-Chip (HB-Chip) with 
a design fl ow rate of 1.5–2.5 mL hr −1 . [ 4 ] Gleghorn et al. devel-
oped a geometrically enhanced differential immunocapture 
(GEDI) device that manipulated the fl ow dynamics around 
microposts to capture CTCs with high purity at a throughput 
of 1 mL hr −1 . [ 16 ] The high throughput microsampling unit 
(HTMSU) designed by Adams et al. was an integrated device 
that could both isolate and enumerate CTCs from 1 mL of 
blood in about 37 min. [ 19 ] Many aptamer based technologies 
were also designed to improve the specifi city of capture. One 
such device was developed by Sheng et al. with a higher fl ow 
rate of 600 nL s −1 (or 2.16 mL hr −1 ). [ 12 ] In 2011, Dickson et 
al. introduced a device that studied cell lines with different 
antigen densities for capture at 18 µL min −1 (1.08 mL hr −1 ). [ 14 ] 
Higher throughputs of isolation have been achieved in sub-
sequent years. An immunomagnetic separation device with a 
throughput of 10 mL hr −1 was developed by Hoshino et al. 
in 2011. [ 20 ] While the throughput is signifi cant for an affi nity-
based CTC isolation, the sample pre-processing steps such as 
dilution and centrifugation may lead to cell loss. [ 20,21 ] Mittal 
et al. developed a permeable affi nity-capture device oper-
ating at 6 mL hr −1 [ 22 ] which was subsequently multiplexed to 
increase throughput. [ 23 ] More recently, two new integrated 
platforms were brought forth for CTC isolation. Liu et al. 
introduced an integrated device that separates blood cells 
and CTCs by deterministic lateral displacement, followed by 
an affi nity-based enrichment. [ 15 ] The CTC-iChip by Ozkumur 
et al. combines inertial focusing with affi nity-based capture 
employing both positive and negative selection. [ 7 ] The device 
works by magnetically labeling cancer cells in whole blood, 
followed by a series of separation steps involving determin-
istic lateral displacement, inertial focusing and magnetic 
separation. [ 7 ] While both these technologies showed a high 
throughput, 9.6 mL hr −1 and 140 µl/min (or 8.4 mL hr −1 ) 
respectively, [ 7,15 ] the need for multiplexing and pre-pro-
cessing of blood samples is cumbersome. Labeling of cells in 
whole blood may also compromise the purity of isolation. [ 7 ] 
Processing higher volumes of blood becomes critical from 
a clinical standpoint as technologies are becoming geared 
toward single cell mutational analysis of CTCs to monitor 
patient status. [ 8,9,24 ] Thus, despite advances in the fi eld, a need 
exists to further improve microfl uidics platforms to effi ciently 
monitor and analyze CTCs with minimal pre-processing of 
blood to preserve these rare cells. 
 In the exploration for such a device that ensures speci-
fi city through antibody-based methods without compromising 
the volume of blood processed, we developed a radial fl ow 
model in contrast to current microfl uidic affi nity-based cap-
ture devices that employ linear fl ow. We hypothesized that 
the constant velocity across every cross-section experienced 
in linear fl ow based devices is a major limitation for effec-
tive capture of cells at higher fl ow rates. Radial fl ow provides 
an alternative to overcome this drawback as the velocity 
decreases with increasing cross-sectional area, thereby pro-
viding varying shear rates across the radius. Cells would thus 
experience different shear rates at every radius and would get 
captured at an optimal shear rate that would be determined 
by their surface antigen expression. A high surface area 
for capture was also achieved by designing a bean-shaped 
micropost with its concave side toward the incoming fl ow. 
 We hereby report a radial fl ow microfl uidic device, 
the OncoBean Chip, inspired by the CTC-chip [ 6 ] that effi -
ciently isolates CTCs in one step at high fl ow rates using 
an affi nity reaction between the Epithelial Cell Adhesion 
Molecule (EpCAM) antigen expressed by epithelial tumor 
cells and anti-EpCAM coated on bean-shaped microposts 
on the microfl uidic chip. The OncoBean Chip ( Figure  1 A) is 
designed to operate at a fl ow rate of 10 mL hr −1 , capturing 
rare CTCs through a radial fl ow design that provides varying 
shear across the device for optimal capture conditions even 
at high fl ow rates. 
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 2.  Results 
 2.1.  Engineering Design and Flow Characteristics 
 The design of an optimal capture platform with structures 
relies largely on channelizing the fl ow in order to have 
maximum cell contact with functionalized post surfaces. 
Reducing the fl ow separation is one way to increase the 
contact of the cell with the post surfaces, thereby increasing 
the chance of capture. A circular micropost as in the CTC-
chip [ 6 ] shows a large fl ow separation behind the post and the 
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 Figure 1.  Schematic representation of OncoBean Chip and fi nite element simulations. (A) Schematic representation of the OncoBean Chip shows 
cancer cells (pink) being captured on antibody coated bean-shaped microposts. Inset shows a fl ow profi le representation with velocity decreasing from 
red to blue. Finite element simulations on a section of the OncoBean Chip show (B) velocity magnitude of fl ow around a single post (magnifi ed image) 
and fl ow converging behind the post, (C) surface plot of shear rate around the posts indicating slowing down of fl ow near the post face (concave side) 
(D) velocity magnitude profi le across posts near the inlet (bottom arc) (E) particle tracing plot around microposts near the inlet demonstrating typical 
streamlines (blue) and capture of 15 µm rigid particles (red) upon encountering a wall (post). Flow occurs from bottom toward top in these images.
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area behind the post remains largely unused for capture. To 
overcome this, we hypothesized that a bean-shape would pro-
vide a better fl ow utilization for capture. The fl ow dynamics 
of a series of different designs of bean-shapes that varied 
by arc angles and length, followed by a qualitative estimate 
of boundary layer thickness from fl uid simulations was per-
formed using COMSOL Multiphysics 4.2 software. 
 The OncoBean Chip was designed with bean-shaped 
posts conceived from an arc angle of 90°, with the structures 
measuring 50 µm wide and 118 µm along the longest axis. 
The posts were placed 25–32 µm apart in polar arrays, with 
subsequent arrays being rotated to introduce interjection of 
fl ow. Figure  1 B, C and D demonstrate velocity magnitude and 
shear rate profi les on simulated sections. As was expected, 
for a fl ow rate of 10 mL hr −1 the simulations predicted max-
imum velocity (0.0158 m/s) for the simulated inlet dimen-
sions and a decreasing trend on moving radially outward as 
the cross sectional area increased. Similar to the velocity pro-
fi le, the shear rate decreased on moving toward the outlets. 
This continuous decrease in shear even at a high fl ow rate of 
10 mL hr −1 makes it feasible to capture cells with a heteroge-
neous expression of antigens. A particle trajectory was also 
simulated to predict hydrodynamic effi ciency and to observe 
streamline paths. The plot (Figure  1 E) shows 15 µm rigid 
particles and their corresponding streamlines as the particles 
navigate around the post structures (walls). The simulation 
predicted 94.3% of particles (33 of 35 particles sent) interact 
with bean posts within the fi rst 600 µm array of dense posts, 
with the remaining 2 particles being interjected at other post 
regions. The simulation thus indicated a high hydrodynamic 
effi ciency and a good streamline trajectory with suffi cient 
cell-post interaction for a sensitive capture. 
 2.2.  Optimization of OncoBean Chip for Cancer Cell Capture 
 The OncoBean Chip was optimized for capture with the 
epithelial lung cancer cell line H1650 with anti-EpCAM as 
the capture antibody. Capture effi ciency was calculated as 
the percentage of captured cells on the device to the total 
number of cells sent, normalized against the OncoBean Chip 
1 mL hr −1 to account for cell spiking errors. Briefl y, fl uores-
cently labeled H1650 cells were spiked into healthy blood at 
a concentration of 1000 cells mL −1 . To validate the effective-
ness of the OncoBean Chip against a standard affi nity-based 
microfl uidic device, the OncoBean Chip was compared with a 
PDMS based version of the CTC-chip [ 6 ] (henceforth referred 
to as the CTC Chip). The following conditions were analyzed: 
OncoBean Chip 1 mL hr −1 , OncoBean Chip 10 mL hr −1 , 
CTC Chip 1 mL hr −1 and CTC Chip 10 mL hr −1 . Upon com-
parison of performance with the CTC Chip, the OncoBean 
Chip showed high capture effi ciencies with mean yields of 
100% and 82.7% at both 1 mL hr −1 (n = 4) and 10 mL hr −1 
(n = 4) respectively ( Figure  2 A), in close agreement with the 
mean capture yield of 90.7% obtained in the CTC Chip at 
1 mL hr −1 . On the other hand, the high capture rate achieved 
by the CTC Chip at 1 mL hr −1 dropped to a mean rate of 
27.8% with the same chip at a fl ow rate of 10 mL hr −1 (n = 3). 
This greater than 3-fold drop can be explained by the linear 
fl ow profi le in the CTC Chip, which may not be conducive for 
capture at high fl ow rates due to the high velocities present 
constantly throughout the device. The OncoBean Chip com-
bats this in its radial fl ow design as there is a continuous drop 
in the velocity on moving outward. 
 The effect of fl ow rates on the capture effi ciency in the 
OncoBean Chip was tested under four conditions: 1 mL hr −1 , 
2.5 mL hr −1 , 5 mL hr −1 and 10 mL hr −1 on anti-EpCAM coated 
devices to test the robustness of the capture platform at dif-
ferent velocities. As seen in Figure  2 (C) the capture effi ciency 
had no signifi cant drop on increasing the fl ow rate from 1 to 
10 mL hr −1 , with the mean capture yield being greater than 
80% at all the above fl ow rates. The lowest mean capture effi -
ciency was 89.5% at 10 mL hr −1 indicating a high yield even 
at this maximum fl ow rate. A similar trend in effi ciency is 
observed in the absence of other cells, as is seen in the capture 
of H1650 cells spiked into serum free medium (shown in Sup-
plementary Figure S1). The OncoBean Chip recovery was also 
tested with the breast cancer cell line MCF7, and the device 
achieved a mean capture yield of 98% at 10 mL hr −1 normal-
ized against the same device at 1 mL hr −1 at a spike concen-
tration of 1000 cells mL −1 (Figure  2 D). This data suggests that 
it is possible to obtain similar recovery of CTCs with a process 
that is 5–10 times faster than many standard affi nity isolation 
methods using whole blood.  Figure  3 A shows the whole blood 
fl owing through the device, and a representative scanning 
electron micrograph of the posts is shown in Figure  3 B. 
 2.3. Purity 
 Non-specifi c background blood cells are a major hindrance 
during molecular analysis of CTCs and it is essential not only 
to achieve effective CTC isolation, but also minimal contami-
nation of these background cells. The purity of capture in the 
OncoBean Chip was determined by measuring the number of 
white blood cells (WBCs) per mL of whole blood captured on 
the device. Due to variations in WBC counts between different 
donors, a purity percentage was not calculated; a relative 
comparison caused by increase in fl ow rates was performed. 
As shown in Figure  2 (B), the high fl ow rates tend to have an 
advantageous effect on reducing the non-specifi c capture of 
contaminating WBCs, with a 2-fold drop in the WBC count 
at 10 mL hr −1 compared with 1 mL hr −1 (OncoBean Chip: 
1 mL hr −1 range 1060–1240 cells per mL, 10 mL hr −1 range 
390–740 cells per mL, CTC Chip: 1 mL hr −1 range 930–2010 
cells per mL, 10 mL hr −1 range 330–850 cells per mL). This may 
be attributed to the high velocities at high fl ow rates which 
reduce the residence time for binding of these cells. The non-
specifi c cell numbers show large variation in capture between 
the OncoBean and CTC Chips but they indicate similar trends 
between the fl ow rates suggesting that the radial gradation in 
shear does not increase non-specifi c white blood cell capture. 
 2.4.  Cell Viability at High Flow Rates 
 For optimal use of microfl uidic platforms to capture 
CTCs, cell viability is an important readout as it determines 
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the feasibility of performing critical downstream assays on 
CTCs, such as genetic profi ling. [ 25 ] Since high fl ow rates can 
induce high shear rates which can be detrimental to cell 
health, [ 6 ] the cell viability was assessed in the OncoBean plat-
form using the Invitrogen Live/Dead Assay. Briefl y, H1650 
cells were spiked into serum free medium and processed 
through anti-EpCAM coated OncoBean Chip at a fl ow rate 
of 10 mL hr −1 . Live/Dead reagent was fl ushed through the 
device and incubated for 15 minutes, followed by microscopic 
imaging of several 10x magnifi cation fi elds of view. The fi rst 
four fi elds of view were considered as accurate estimates of 
cell viability. Live and dead cells were manually counted and 
cell viability was defi ned as the percent ratio of number of 
cells alive to the total number of cells in the fi eld of view. 
Using this assay, 92.91 ± 1.63% (mean ± s.d.) of the cells were 
found to be viable after fl ow at high throughput, comparable 
to the mean viability of 98.5% reported for the CTC-chip. [ 6 ] 
These data indicate that despite facing an initial momentary 
high stress at higher fl ow rates, cell viability is not diminished 
compared to lower fl ow rates, perhaps due to the contin-
uous drop in shear stress that is produced by the radial fl ow 
(Figure S4). 
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 Figure 2.  Optimization of capture effi ciency. (A) Comparison of H1650 cell capture from whole blood between OncoBean Chip vs CTC Chip at 
1 and 10 mL hr −1 normalized to OncoBean Chip at 1 mL hr −1 (B) Non-specifi c white blood cell capture for the experiment in (A) represented as the 
number of white blood cells per mL of whole blood. (C) Effect of fl ow rates on capture of H1650 cells spiked into whole blood by the OncoBean 
Chip shows capture yields at 1, 2.5, 5 and 10 mL hr −1 (D) Capture of MCF7 cells from whole blood by the OncoBean Chip at 1 and 10 mL hr −1 . 
(E) and (F) show capture profi le or position of H1650 cells captured across different radial distances along the OncoBean Chip at 1 mL hr −1 and 
10 mL hr −1 , respectively.
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 2.5.  Capture Profi le 
 The varying shear stress model proposed in the OncoBean 
Chip suggests there are differential regions of capture on 
the OncoBean, dependent on antigen density. For a given 
fl ow rate, capture of a high EpCAM expressing cell would 
require less residence time for binding than a low EpCAM 
expressing cell. [ 22,26,27 ] This translates to distance traversed 
within the device, or the number of antibody-coated posts 
encountered by the cell. At low fl ow rates, the cells would be 
captured within a small distance into the device due to the 
radial drop in shear in addition to the already-low shear rates. 
At high fl ow rates, a larger capture distance is required as the 
velocity needs to slow down suffi ciently for the cells to bind. 
To test this hypothesis, H1650 cells were spiked into blood 
and captured at 1 mL hr −1 and 10 mL hr −1 . The cells captured 
were manually counted at 1000 µm radial intervals. The cap-
ture profi le plot (Figure  2 E and F) shows the distribution of 
captured cells along various radial positions in the Onco-
Bean Chip. It was observed that with H1650, a cell line with 
high EpCAM expression (greater than 500,000 antigens per 
cell), [ 6 ] most cells are captured within the fi rst half radius of 
the device at 1 mL hr −1 (Figure  2 E), while the capture is more 
widespread at 10 mL hr −1 (Figure  2 F), utilizing a larger area 
of the device at the higher fl ow rate. This was in accordance 
with our predictions. A similar capture profi le was observed 
for MCF7 cells as well. 
 2.6.  CTC Capture in Cancer Patients 
 The strength of the technology was assessed by testing clinical 
specimens from different cancers. Whole blood from healthy 
donors (n = 4) was processed as controls at 10 mL hr −1 
to test for the specifi city of capture against anti-EpCAM. 
After fi xation of the cells on the device, the cells were perme-
abilized and stained for anti-Cytokeratin (CK) (tumor spe-
cifi c epithelial marker), anti-CD45 (leukocyte marker) and 
DAPI (nuclear stain) and respective secondary antibodies 
for immunofl uorescent imaging. Figure  3 C-F presents repre-
sentative images of immunofl uorescence staining of H1650 
lung cancer cells along with WBCs captured on the chip, 
where as Figure  3 G-H shows the SEM image of a H1650 
cell captured on the side of an OncoBean post .The criteria 
for CTC enumeration in patient samples was a CK+, CD45- 
and DAPI+ expression profi le. [ 6 ] The healthy controls gave a 
small 2014, 10, No. 23, 4895–4904
 Figure 3.  Cell capture on the OncoBean Chip. (A). The OncoBean Chip with blood fl ow shows inlet and outlet positions (B) Scanning electron 
micrograph of the device shows bean-shaped micropost structures. H1650 cells in blood captured by the OncoBean Chip: panel shows 
immunofl uorescence images of cells stained for nucleus with DAPI (C), CD45 – a white blood cell marker (D), cytokeratin 7/8 that stains the 
H1650 cancer cells (E), and a merged fi eld (F) showing all fl uorescent stains. (G) is a scanning electron micrograph of a H1650 cell captured on a 
bean-shaped micropost, with (H) showing a magnifi ed view of the cell.
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recovery of 1.4 ± 0.89 CTCs per mL (range 0.91–2.67 CTCs 
per mL, median 1.13 CTCs per mL) as per the above enu-
meration criteria (supplementary Figure S3). Following this, 
a threshold of 2 CTCs per mL was set for CTC detection in 
clinical specimens. [ 28 ] Whole blood from pancreatic (n = 2), 
breast (n = 2) and lung (n = 2) cancer patients were processed 
through the OncoBean Chip at 1 and 10 mL hr −1 in equal 
volumes to observe CTC recovery using an anti-EpCAM 
antibody. According to this criteria, CTCs were detected by 
the device in 100% of the samples, with a recovery of 4.33 ± 
0.67 CTCs per mL at 1 mL hr −1 (range 3.33–5 CTCs per mL, 
median 4.34 CTCs per mL) and 4.45 ± 0.81 CTCs per mL 
at 10 mL hr −1 (range 3–5 CTCs per mL, median 4.84 CTCs 
per mL). The high fl ow rate of 10 mL hr −1 gave equivalent 
recovery in 5 of 6 samples. Because of the small cohort of 
specimens tested, statistical signifi cance was not observed. 
The CTC yields across the different cancers at the two fl ow 
rates are shown in  Figure  4 A. It can be seen that the high 
fl ow rate has a similar CTC recovery capacity to that at a low 
fl ow rate in the various cancer specimens processed. 
 3.  Discussion and Conclusion 
 High throughput analysis has remained a major hurdle in 
the retrieval of circulating tumor cells from cancer patients 
and is a critical issue in the development of new microfl uidic 
technologies to measure CTCs. [ 25 ] While many physical sepa-
ration methods and integrated systems have been developed, 
to our knowledge, no affi nity-based one-step cell recovery 
technologies have yet been developed for high throughput 
analysis. The OncoBean Chip is a fi rst immuno-enrichment 
technique of its kind offering the specifi city of antibody-based 
capture in a high throughput manner (10 mL hr −1 ). It works 
by isolating CTCs from whole blood in a single step, without 
the need for pre-processing or dilutions. It achieves its high 
throughput functionality through a simple technique of a 
radial fl ow channel. Fluid simulations and theoretical calcula-
tions show that the fl uid velocity in the radial fl ow OncoBean 
Chip varies as 1/(2π rh ), where  r and  h stand for the radius 
and height of the channels, respectively. While increasing 
the height of the channel is an alternative to achieving high 
throughput, microfabrication of a high aspect ratio channel 
might be challenging. A fl ow profi le which dynamically varies 
with distance thus offers an economical and compact tech-
nology that enables the processing of high volumes of fl uid 
samples, which is highly advantageous in the context of rare 
circulating tumor cells. The design of the OncoBean Chip is 
thus optimal for this purpose, as it achieves an average cap-
ture effi ciency (>80%) comparable to that of the CTC Chip, 
which still remains a benchmark for microfl uidic CTC extrac-
tion by immuno-affi nity methods. [ 5,11 ] 
 Immuno-affi nity based microfl uidic platforms like the 
CTC Chip and others perform poorly at high fl ow rates due 
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 Figure 4.  OncoBean Chip validation with patient samples. (A). Clinical performance of the OncoBean Chip showing CTC recovery from patients with 
pancreatic (Pa), breast (Br) and lung cancer (L) at 1 and 10 mL hr −1 . Panel at the bottom shows immunofl uorescent staining of a lung CTC recovered 
at 10 mL hr −1 showing (B) nucleus, (C) absence of CD45, (D) cytokeratin 7/8 and (E) a merged fi eld with all channel staining.
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to the linear fl ow profi le wherein many cells either escape 
the substrate interactions or are travelling at a constantly 
high velocity throughout the device in order for binding to 
occur. [ 4,6 ] The OncoBean Chip shows stable binding at high 
fl ow rates due to the drop in velocity at every radial position 
toward the outlets. Reducing shear at different cross sections 
in the chip also allows a high fl ow rate without compromising 
cell viability, increasing the feasibility of downstream pro-
cessing of these cells to obtain molecular characteristics and 
genetic information. [ 25,29 ] 
 While high volumes of blood used for CTC analysis 
potentially offer higher yields of these rare cells, the detec-
tion methods also face the issue of an increased background 
contamination owing to the quantity of sample. We observed 
that WBC contamination was not a major concern in the 
OncoBean Chip as the high velocities prevented high non-
specifi c binding. There is a greater than 2-fold drop in the 
contaminating WBCs when run at 10 mL hr −1 in contrast to 
1 mL hr −1 (Figure  2 B), and also a continuous drop in non-
specifi c binding with increasing fl ow rates. This is expected 
as the higher velocities reduce the interaction time of these 
non-specifi c cells with the tumor-specifi c-antibody coated 
posts, thereby reducing contamination. The higher levels of 
purity coupled with higher CTC yields in a one-step strategy 
should enhance accuracy in molecular analyses of the recov-
ered CTC population. [ 30 ] 
 Affi nity-based microfl uidics are dependent on antibody-
antigen kinetics, and antigen density is an important param-
eter controlling the rate of capture. [ 22,26,27 ] The capture profi le 
plot (Figure  2 ) shows that a cell with high EpCAM expres-
sion such as H1650 would be captured early in the device as 
the antigen density would enhance bond formation, whereas 
a cell with lower EpCAM expression would be concentrated 
around the latter half of the device, nearer to the outlets, as 
the cells would need to be at a suffi ciently lower velocity 
for binding to occur due to the smaller number of binding 
sites. [ 22,26 ] The OncoBean Chip is thus conducive to capturing 
cells with a wide range of EpCAM antigen expression. It is 
also possible that multiple antibody combinations could be 
used in the OncoBean Chip in the future to further fi ne tune 
CTC capture. 
 As with all diagnostic technologies, bench-to-bedside 
remains the deciding factor for the device's competence. The 
OncoBean Chip shows initial promise with clinical samples, 
capturing CTCs from the blood of patients with epithelial 
cancers by the use of anti-EpCAM as the capture antibody. 
Out of the 6 patient samples tested, 5 show equivalent cap-
ture at 10 mL hr −1 compared to capture at 1 mL hr −1 . This 
demonstrates the potential of this technology as a high-
throughput platform to evaluate CTCs in different cancers. 
The technology also enables the processing of 7.5 mL of 
blood in under an hour, which is not only unprecedented in 
many other microfl uidic technologies, but also attractive from 
a clinician's perspective. The OncoBean Chip is thus a poten-
tial tool for blood based diagnostics that can quickly become 
part of routine clinical tests. The healthy controls also indi-
cate the specifi city of capture by this technique. Although the 
small cohort of patients and the volume of blood processed 
for unbiased comparison with that at low fl ow rate restrict 
a rigorous sensitivity analysis of the device, the capture effi -
ciency of the device shows potential for using higher volumes 
of blood for recovery of higher CTC numbers. While a few 
high throughput affi nity isolation technologies have recently 
been developed, they invariably require working with diluted 
blood, or multiplexing and integration of devices. [ 7,15,20,22,23 ] 
Also, immunomagnetic technologies suffer from limitations 
such as reduction in the binding affi nities of antibodies on 
magnetic particles, requiring higher amounts of antibodies 
for larger cell populations. [ 21,31 ] Tumor heterogeneity brings 
forth another set of challenges for physical separations as 
CTCs are observed to be widely different, with size hetero-
geneity being the most evident. [ 25,32,33 ] Hou et al. witnessed 
a range of 10–22.5 µm in the CTC sizes isolated using their 
physical separation device. [ 32 ] While many such devices per-
form at commendable throughputs, such size variations may 
result in signifi cant CTC loss. 
 We have thus shown that high-throughput processing 
with immuno-affi nity capture is possible even without mul-
tiplexing such as in physical separations which in many cases 
involve complex handling to reduce the blood volume. [ 7,15 ] 
We have validated the effi cacy of the technology with cancer 
cell lines and also with clinical specimens. In addition, it has 
also been shown that the ultra-high throughput used is not 
detrimental to the cell viability, yields good purity and can 
be capitalized for downstream studies. The major highlight 
of the OncoBean Chip lies in its design of radial fl ow, which 
can be easily incorporated into other microfl uidic chips, such 
as the graphene oxide chip developed by our group [ 28 ] and 
other devices that may be utilized for CTC culture. The cap-
tured cells can be released by widely used cell recovery tech-
niques as described in [ 13,19 ] or by incorporating thin coating 
of hydrogels as shown by Shah et al. [ 34 ] The OncoBean Chip 
would thus be useful in the cases of early stage cancers where 
there may not be suffi cient number of cells in the circulation 
in order to be detected in 1–3 mL of blood and thus shows 
great promise as an early diagnostic tool. 
 4.  Experimental Section 
 COMSOL Simulations : Finite element simulations were per-
formed in COMSOL Multiphysics 4.2 (Comsol Inc.) with an inlet 
fl ow rate of 10 mL hr −1 on a 6 mm radial section and 30° arc of 
the proposed device. Navier-Stokes equations for incompressible 
fl uid fl ow were used for the study. A symmetry boundary condition 
was applied on the two similar boundaries fl anking the posts. Wall 
(no slip) boundary condition was applied on the post outlines. 
The particle tracing plot was simulated with rigid particles 15 µm 
in size, with a condition of sticking to any encountered wall being 
applied. 
 Device Fabrication : The design was prepared using AutoCAD 
software with the following dimensions: bean width 50 µm, arc 
angles 90°, adjacent (lateral) post spacing 25–32 µm. The design 
was converted to a photomask (FineLine Imaging) and used to 
prepare a mold by traditional photolithography. Briefl y, a nega-
tive photoresist SU-8 100 (MicroChem Corp) was spin coated onto 
a silicon wafer at 2350 rpm. This was followed by soft baking at 
65 °C for 10 min and 95 °C for 70 min, and then UV exposure of 
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the pattern onto the wafer for 15 sec. Post exposure baking was 
done at 65 °C for 3 min and 95 °C for 10 min and the pattern was 
developed in SU-8 developer. The wafer was then hard baked at 
150 °C for 3 min. A post height of 100 µm was achieved. Poly-
dimethylsiloxane or PDMS (Ellsworth Adhesives) was prepared in 
a monomer to curing agent ratio of 10:1 and baked overnight after 
degassing. The PDMS was peeled from the master mold, cut and 
prepared for surface modifi cation. 
 Each PDMS chip was bonded onto a glass slide using plasma 
bonding. 3-mercaptopropylmethyldimethoxy silane (Gelest) was 
infused and incubated for 1 hour. This was followed by washing 
with ethanol and addition of N-gamma-Maleimidobutyryloxy-
Succinimide (GMBS) (ThermoScientifi c), a cross linking agent for 
30 mins. The devices were washed again and Neutravidin (Invit-
rogen-Life Technologies Inc.) was added and the devices were 
stored at 4 °C. Before experiments, the devices were incubated 
with biotin-conjugated anti-EpCAM (RnD Systems). 
 Cell Preparation : Human lung cancer cell line H1650 and 
human breast cancer cell line MCF7 were cultured in RPMI-1640 
and DMEM (Invitrogen – LifeTechnologies, Inc.) respectively. The 
media were supplemented with 10% fetal bovine serum (Invit-
rogen – LifeTechnologies, Inc.). Both additionally contained 1% 
antibiotic-antimycotic solution. Cells were grown at 37 °C and 5% 
CO 2 and medium was renewed every 2–3 days. Cells were pas-
saged with 0.05% Trypsin-0.53 mM EDTA (Invitrogen – LifeTech-
nologies, Inc.). 
 Cell Capture and Analysis : The cells were harvested with 0.05% 
Trypsin-0.53 mM EDTA and labeled with CellTracker Green fl uores-
cent dye (Invitrogen – LifeTechnologies, Inc.). They were counted 
with a hemocytometer and spiked into healthy blood or serum 
free medium. Informed consent was obtained from all healthy 
blood donors at University of Michigan, Ann Arbor, USA using IRB 
approved protocols. The devices were incubated with anti-EpCAM 
prior to experiments. After antibody immobilization and wash, low 
dead volume tubing from Cole-Parmer (AAD02091-CP) was con-
nected to the device and fl ow was facilitated through a syringe 
needle. 3% bovine serum albumin (Sigma Aldrich) was used as 
a blocking agent to reduce non-specifi c binding. Two of the three 
outlets in the device were connected by a short tubing to have a 
single outlet port for waste blood collection, while also increasing 
the fl uid resistance. The fl uid spiked with known number of cells 
was then processed through the device at the respective fl ow 
rates. This was followed by washing with phosphate buffer saline 
(PBS) and fi xing and permeabilization with BD Cytofi x/Cytoperm 
(BD Biosciences). DAPI (4′,6-diamidino-2-phenylindole) (Invitrogen 
– LifeTechnologies, Inc.) was then applied to stain the nucleus fol-
lowed by a last washing step. The devices were stored at 4 °C until 
visualization with Nikon Eclipse Ti fl uorescence microscope. 
 Statistical analysis was performed with the software Orig-
inPro 9.0. A standard two-sample t-test was used for comparison 
between the groups. 
 Patient CTC Analysis : Informed consent was obtained from all 
donors. Whole blood from cancer patients was processed through 
the OncoBean Chip at the designated fl ow rates in equal volumes, 
followed by washing with phosphate buffer saline. The cells were 
fi xed with 4% paraformaldehyde and refrigerated at 4 °C until immu-
nofl uorescent staining. Before staining, the cells were permeabilized 
with 0.2% Triton-X 100, followed by blocking with 2% goat serum 
in 3% bovine serum albumin. Primary antibodies anti-Cytokeratin 
7/8 (BD Biosciences) and anti-CD45 (BD Biosciences) were applied 
in 1% bovine serum albumin for all samples with the exception of 
pancreatic cancer specimens where anti-Cytokeratin 19 (SantaCruz 
Biotechnology Inc.) and anti-CD45 (SantaCruz Biotechnology Inc.) 
were used. After a quick wash, secondary antibodies AlexaFluor 488 
and AlexaFluor 546 or 568 (Invitrogen-Life Technologies Inc.) were 
applied in 1% bovine serum albumin. DAPI was applied as the fi nal 
step before microscopic imaging. 
 Cell Viability Assay : H1650 cells were harvested and spiked 
into serum free RPMI 1640 and processed through the OncoBean 
Chip at 10 mL hr −1 . The live/dead reagent consisting of calcein AM 
and ethidium homodimer-1 (Invitrogen – LifeTechnologies, Inc.) 
was prepared as specifi ed by manufacturer and applied to the 
cells in the device. Following 15 min of incubation, several fi elds of 
view were microscopically imaged under 10x magnifi cation. 
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 Supporting Information is available from the Wiley Online Library 
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